Kornimate/medical-research-clean huggingface dataset:
effectiveness of plasma transfusions in critical care patients

Conditions: Coagulation

Summary: measuring the effectiveness of plasma transfusions in critical care

measuring the effectiveness of plasma transfusions in critical care

Eligibility criteria:
inclusion criteria: * icu admission * inr \> 1.2 * require ffp for active bleeding and/or prior to an invasive procedure * are able to provide consent or proxy consent exclusion criteria: * congenital or acquired coagulation factor deficiency * platelet count \< 50 x 109 /l and have not received subsequent platelet transfusion * consumptive coagulopathy (bleeding ≥ 3 sites and ↓ plts, ↓ fib, ↑ d dimer) * uncontrolled bleeding (6 or more units of blood in the last 6 hours) * receiving therapeutic doses of heparin/heparinoid (must be off for at least 6 hours) * have received clotting factor concentrates in the previous 24 hours * are expected to require surgery in the next 48 hours * survival expected to be less than 48 hours * currently enrolled in another study with a similar outcome * previous enrollment in this study

Keywords: plasma trauma critical care
ebv positive nasopharyngeal carcinoma treated with concurrent chemo-radiotherapy with or without anti-viral drug

Conditions: Drug Use for Unapproved Schedule

Summary: pcr-dna of ebv test is a good prognostic indicator for survival after treatment (report: prognostic impact of plasma, epstein-barr virus dna in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. the chances of the local recurrence or metastasis are higher in the patients at same stage with positive pcr-dna of ebv in nasopharyngeal carcinoma after same treatment.(ref.) antiviral drugs have been used to inhibit ebv replication and target viral dna polymerase are foscarnet and phosphonoacetic acid both interact directly with the pyrophosphate-binding site of the enzyme, where acyclovir as antiviral drug act at two levels: as competitive alternative substrates, competing with gtp on the substrate-binding site, and as dna chain terminators, by incorporating into the growing dna chain and blocking its elongation due to their acyclic structure.


Eligibility criteria:
inclusion criteria: * confirmed histopathologic diagnosis of nasopharyngeal squamous cell carcinoma, types who ii-iii. * stage ii-ivb * requiring primary concomitant radiotherapy and chemotherapy. * no head and neck surgery of the primary tumor or lymph nodes except for incisional or excisional biopsies. * positive pcr-dna ebv * ≥ 18 years of age * ecog performance status 0-1 * wbc ≥ 4,000/µl, platelets ≥ 100,000/µl; serum creatinine ≤ 1.6 mg/dl or 24 hr. calculated creatinine clearance ≥ 60 ml/min (see section 3.1.6). * pre-treatment evaluation of tumor extent and tumor measurement. * nutritional and general physical condition must be considered compatible with the proposed radio-therapeutic treatment. * signed study-specific consent form prior to study entry assessment. exclusion criteria: * prior radiotherapy to the head and neck or any prior chemotherapy ≤ 6 months prior to study entry. * other malignancy except non-melanoma skin cancer or a carcinoma not of head and neck origin ≤ 5 years * evidence of distant metastasis. * on any experimental therapeutic cancer treatment. * major medical or psychiatric illness. * pregnant females. * age ≤ 18 years old

Keywords: ebv nasopharyngeal carcinoma
povidone iodine mouthwash, gargle, and nasal spray to reduce naso- pharyngeal viral load in patients with covid-19

Conditions: COVID-19

Summary: the sars-cov-2 coronavirus pandemic is responsible for more than 180,000 deaths worldwide and 20,000 deaths in france. to date, no treatment or vaccine has been successful. povidone-iodine is an antiseptic suitable for use on the skin and mucosa with potent virucidal activity, particularly against coronaviruses. it is marketed for oro-nasopharyngeal decolonization. 24 patients with positive nasopharyngeal sars-cov-2 carriage will be randomized (1:1) in an experimental group (benefiting from povidone iodine decolonization) or a control group. patients in the experimental group will be asked to gargle with a 1% povidone-iodine solution, spray their nose with the same antiseptic solution, and finally applied 10% povidone-iodine cream in each nostril, all four times a day for five days. patients will be followed for 7 days to evaluate the efficacy and safety of povidone iodine decolonization.


Eligibility criteria:
inclusion criteria: * adults (age over 18 yrs) of both sexes * with positive sars-cov-2 carriage by rt-pcr * having given their written consent after having been informed exclusion criteria * patient with low viral load (threshold cycle \[ct\] \> 25 per rt-pcr), * patient unable to perform oro-nasopharyngeal decolonization * known hypersensitivity to one of the constituents, particularly to povidone-iodine, * history of dysthyroidism, * known coagulopathy, * participation in another clinical trial aimed at reducing viral load in patients with sars-cov-2, * pregnant or breastfeeding women, or women of childbearing age without effective contraception * patients not covered by a social security scheme * patients with enhanced protection

Keywords: sars-cov-2 povidone iodine decolonization
defining strategies for improving endothelial and fibrinolytic dysfunction in obesity

Conditions: Metabolic Syndrome X

Summary: the combination of high blood pressure and having central obesity is an increasing important factor for heart disease in men and women. it can also lead to the early development of hardening of the arteries and increased risk of a stroke. this study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.

obesity is an increasingly important risk factor for cardiovascular disease in men and women and is associated with the premature development of atherosclerosis, and increased risk of stroke. a classical perspective of cardiovascular risk does not adequately explain all of the cardiovascular events associated with obesity. elevated plasma levels of plasminogen activator inhibitor type i (pai-1) are one of the biochemical hallmarks for obesity and likely contribute the increased risk of atherothrombotic events in patients with obesity. the central hypothesis of this proposal is that the increased risk of atherothrombotic events in patients with obesity. the central hypothesis of this proposal is that vascular pai-1 excess promotes the development of intravascular thrombosis. we will test the hypothesis that secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing pai-1 production or impairing endothelial t-pa release. from a public health perspective, there is no greater threat to america's cardiovascular health than the epidemic of obesity. it is anticipated that this study will provide new insights nto the molecular mechanisms that contribute to the development of fibrinolytic dysfunction and cardiovascular disease in obesity.

Eligibility criteria:
inclusion criteria: * male or females between the ages of 18 to 65 years of age. * documented diagnosis for the metabolic syndrome: * subjects with hypertension (sp\>130mmhg) * subjects with central obesity (females waist \>35"; males waist \>40") * subjects with dyslipidemia (hdl \ 150 mg/dl) * subjects who are insulin resistance (fasting glucose \>100mg/dl) exclusion criteria: * subjects who smoke * women who are pregnant (confirmed by urine beta-hcg). * women who are breast feeding * subjects with documentation of the following health risk: * subjects with serum creatinine \>2.0 mg/dl (males), \>1.8 mg/dl (females) * subjects whose creatinine clearance \< 50 mls/min * subjects with serum potassium \>5.5meql * subjects with type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration \>0.2) * subjects who are currently taking the following medications: * warfarin

Keywords: fibrolytic dysfunction obesity pai-1
peri-implant marginal bone and soft tissue conditions around single laser-lok implants placed in regenerated extraction sockets and in native bone: a 2-years results of rct

Conditions: Partially Edentulous Maxilla, Partially Edentulous Mandible

Summary: the aim of present study was to compare peri-implant marginal bone loss and soft tissues conditions around single laser-lok implants placed in alveolar

records of 20 consecutive patients treated with dental implants placed in post-extraction sockets augmented with porcine derived bone and 20 consecutive patients with implants placed in native bone were reviewed. for each implant, the radio- graphs from the surgical appointment were compared to those from the last follow-up visit and evaluated regarding changes of marginal bone level over time.

Eligibility criteria:
inclusion criteria: * mono-edentulism, age ≥ 18 years, good general health, without contraindications to implant surgery exclusion criteria: * lack of a periodontal chart and periapical radiograph at the beginning and at the end of follow-up period, alcohol and drug abuse, pregnancy, or uncontrolled metabolic disorders, tobacco smoking (\> 10 cigarettes/day), full mouth plaque score (fmps), and full mouth bleeding score /fmbs) ≥25%, teeth adjacent to the implant area (mesial and distal) affected by untreated periodontal and/or endodontic infections.

Keywords: regenerated bone, native bone, dental implant
a logical framework for tailor-made paradigm shift hospital foodservice to prevent malnutrition among geriatric patients in hospitals

Conditions: Hospital Foodservice Satisfaction; Hospital Meals Satisfaction; Elderly, Nutrition, Malnutrition in Elderly, Malnutrition

Summary: hospital food service is important for patient recovery by providing necessary aid with adequate meal consumption. overall, hospital experience can influence patients' satisfaction for the foodservice quality. thus, it is important to evaluate patient satisfaction with food service to meet consumers' needs in order to prevent malnutrition. the aim of the studies is to develop the malaysian geriatric patients' hospital foodservice protocol (my geryfs). there are 3 phases in this research which is phase 1 is a multicentre cohort study conducted among elderly and healthcare professionals involved in klang valley hospitals. phase 2 for to develop a tailor-made hospital foodservice protocol for malaysian geriatric patients with healthcare professional input and phase 3 is to determine the feasibility and cost-effectiveness of my geryfs protocol in a malaysian hospital. effectiveness of this study protocol can bring benefits to elderly to prevent malnutrition in the hospitals via foodservice.


Eligibility criteria:
inclusion criteria: * patients aged 60 years and older * able to understand and speak malay or english or both * patients who are on oral diet or on oral nutrition support (ons) or both * patients who are admitted for more than 48 hours exclusion criteria: * patients who are mentally disturbed * critically ill patients * patients who are on full enteral or parenteral feeding
use of gelronate gel vs. aloevera in preventing/minimizing radiation-induced dermatitis in breast cancer patients

Conditions: Radiation Dermatitis

Summary: the aim of the study is to evaluate the effect of gelronate gel, naha based product (medical device for topical application) vs. aloevera gel, in prevention or minimizing of radiation induced skin reaction in breast cancer patients

gelronate is gel composed of 1% high molecular weight pharmaceutical grade sodium hyaluronate and preservatives dissolved in pharmaceutical grade purified water. gelronate supply in an airless pump bottle contain \~30 ml gel. in the study, 120 female patients planned to receive whole breast radiation (with or without lymphatic drainage) in the radiotherapy unit at sheba medical center. patients will undergo ct simulation with 3d treatment planning (as routine done) and will receive 42.4 gy in daily fraction of 2.65 gy, five times per week to the whole breast according to the standard department protocol, with or without concomitant or subsequent lumpectomy cavity boost. patients data including demographics, staging, systemic therapy, radiation details, other medications will be recorded the protocol's forms. the gel will be applied as a thin lotion twice a day, immediately after radiotherapy treatment and once more in the evening/morning. the therapy will continue for 10 days following the end of radiation therapy.

Eligibility criteria:
inclusion criteria: * female patients aged at least 18 years with unilateral breast following lumpectomy +/- chemotherapy * planned to receive 42.4 gy whole breast irradiation +/- boost to tumor bed. * ecog performance status 0-2. * capable of giving written informed consent. * no co-morbidities known to affect radiotherapy reactions. * no co-existing acute or chronic skin disease. * no evidence of infection or inflammation of breast to be treated. * not receiving chemotherapy during radiotherapy course. biological therapy (e.g. herceptin) or hormone therapy will be allowed during the study. exclusion criteria: * chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy planned during radiation. * prior radiotherapy to the chest wall. * collagen vascular disease. * participation in other clinical study.
evaluation of the safety and efficacy of thl-p in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: the purpose of this study is to obtain evidence from test article with efficacy in metastatic breast cancer patients. the average of all changes from baseline to post-treatment evaluations in global health/quality of life (qol) subscale assessed by self-administered european organization for research and treatment of cancer quality of life questionnaire - core 30 (eortc-qlq-c30).

the test article is extracted from many natural herbals, in which most or their components have been shown to have anti-tumor activity. a study in 2004 showed the test article could have strong immunomodulatory effect on the antigen-stimulated proliferation response (pr) of peripheral blood mononuclear cells (pbmc) and t-cells from recurrent aphthous ulcerations (rau) patients and suggested that it might be a potential immunoceutical agent for treatment of rau. subsequent study in 2005 also suggested the test article as a potential immunoceutical agent for treatment of rau because the result showed it could modulate the antigen-stimulated cytokine production by t-cells isolated from rau patients. another study in 2005 showed the test article also had a broad-range tumor killing function and provided a molecular basis underlying therapeutic activity. it was also suggested in this study will could be a potential and promising cancer therapeutic or preventive agent. the aim of this current study is to explore the safety and efficacy of the investigational product with 20 ml, 3 times per day (daily dose: 60 ml) for a total of 24 weeks in the patients with metastatic breast cancer refractory to conventional treatment modalities.

Eligibility criteria:
inclusion criteria: * confirmed breast cancer with clinical evidence. * life expectancy of at least 4 weeks. exclusion criteria: * any uncontrolled infection. * lupus erythematosus. * malignant tumor.

Keywords: breast cancer
oral or intra muscular vitamin d2 vs oral or intra muscular vitamin d3 in treatment of vitamin d deficiency

Conditions: Vitamin D Deficiency

Summary: the main purpose of this research is to find out if there is any difference between treating vitamin d deficiency with oral vitamin d3 or i.m vitamin d2. the second aim of this research is to confirm the superiority of vitamin d3 over vitamin d2 in treating vitamin d deficiency. additional useful information in this research is to find out the best recommended maintenance dose of vitamin d and formula by having regular follow up of treated individuals once their serum vitamin d level reach the recommended normal serum level.

in a systemic review, it was found that treating individuals who have vitamin d deficiency with vitamin d3 rather than vitamin d2 would be a better option. vitamin d3 is superior in treating vitamin d deficiency according to this systemic review. however, this systemic review raised a question of comparing oral to i.m treatment of vitamin d deficiency and no data was available to support either treatment above the other. the main purpose of this research is to find out if there is any difference between treating vitamin d deficiency with oral vitamin d3 or i.m vitamin d2. the second aim of this research is to confirm the superiority of vitamin d3 over vitamin d2 in treating vitamin d deficiency. additional useful information in this research is to find out the best recommended maintenance dose of vitamin d and formula by having regular follow up of treated individuals once their serum vitamin d level reach the recommended normal serum level. the research will involve 100 patients between the age of 20-50 years old. they will be divided into 4 groups. each group will have either oral or i.m vitamin d2 or oral or i.m vitamin d3. the oral doses will be 50000 international units to be taken weekly and the i.m doses will be of 300000 international units which will be taken once every 6 weeks. vitamin d level will be checked once every 4 weeks. the initial expected duration of the first phase of the research will be about 6-12 weeks which will give us a good orientation to answer the main and the second questions. then the follow up may take up to another 6 months to check the maintenance dose of the best recommended oral or i.m treatment of bolus doses in certain intervals as initial trial.

Eligibility criteria:
inclusion criteria: * age 20-50 years * basal vit d level should be between 10-18 ng/ml for phase 1 and between 30-50 ng/ml for phase 2 exclusion criteria: * pregnant women * history of renal implant or renal impairment of egfr less than 60% * abnormal liver function test * patients with inflammatory bowel disease or of history of bariatric surgery

Keywords: vitamin d endocrinology
evaluate the efficacy and safety of rhumab beta7 in patients with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this phase ii study is a randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of rhumab beta7 in patients with moderate to severe ulcerative colitis.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate to severe ulcerative colitis outpatient * disease duration at time of screening of \>/= 12 weeks exclusion criteria: * extensive colonic resection or subtotal or total colectomy * presence of an ileostomy or colostomy * moderate to severe anemia * a history or evidence of colonic mucosal dysplasia * pregnant or lactating * significant uncontrolled co-morbidity, such as neurological, cardiac, pulmonary, renal, hepatic, endocrine, or gastrointestinal (gi) disorders * significant screening ecg abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block * poorly controlled diabetes * impaired renal function * impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis * positive tests for antibodies indicating active or prior infection with hiv or hepatitis b (hbv) or c (hcv) * positive screening test for latent mycobacterium tuberculosis (tb) infection * demyelinating disease * received any investigational treatment within 12 weeks prior to initiation of study treatment * previous exposure to rhumab beta7
effect of hormonal contraception on lower urinary tract symptoms& sexual function

Conditions: Contraception

Summary: effect of hormonal contraception on lower urinary tract symptoms\& sexual function

it is generally accepted that female sex hormones influence the morphology and physiology of vaginal tissues. peripheral estrogen affects urogenital connective tissue composition and structure, vaginal blood flow, and thickness of vaginal epithelium. estrogen and progestagen receptors are also abundantly present in the lower urinary tract, which has the same embryonic origin as the vagina. decline in circulating estrogen levels may result in atrophy of vaginal, urethral and bladder trigonal epithelium, as well as initiate metabolic changes in the subepithelial supportive tissues. this process forms the biological rationale for the common clinical practice of prescribing hormone treatment to menopausal women with lower urinary and genital tract symptoms. contrary to widespread belief, the womens health initiative (whi) randomised trial showed that menopausal hormone therapy with conjugated estrogen alone, or in combination with progestagen, increased the risk of de novo or aggravated urinary incontinence after one year of treatment. in premenopausal women, oral contraception is the most common source of hormone intake but very few studies have endeavored to determine the effects of oral contraception on premenopausal urinary incontinence. the aim of this nationwide cohort study was to assess the influence of contraceptives on the risk for lower urinary tract dysfunction in young female.at is time-related with the beginning of hormonal contraception, health care providers should give information about other methods and try to switch them to a method less associated with sexual dysfunction. however, there are contradictory results between the different studies regarding the association between sexual dysfunction and hormonal contraceptives, so it could be firmly said that additional research is needed. meanwhile, it could be said that hormonal contraception has been associated with different alterations in sexual functioning. to conclude, a multidisciplinary approach to the management of female sexual dysfunction is mandatory, and health care providers should give lifestyle counselling apart from proposing different treatment options. an adequate relationship with the patient, as well as the routine monitoring of possible sexual dysfunction, are essential in addressing these difficulties. undoubtedly, the best contraceptive is one that fulfills the women's needs with acceptable side effects and agreed with the prescribed

Eligibility criteria:
inclusion criteria: 1. women taking hormonal contraception e.g cocs .pops.implanon\&.injectable contraception 2. women has good regular marital life exclusion criteria: 1. female has organic urinary dysfunction 2. female has mental\& psycological dysfunction 3. chronic disease dm.hypertension. chronic renal disease 4. prolapse 5. previous perineal \&vaginal correlation surgery 6. women taking any treatment for urinary tract infection \&sexual dysfunction